Literature DB >> 28194742

Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.

Toru Niwa1, Katsuhisa Waseda1, Tomofumi Mizuno2, Yusuke Nakano1, Kentaro Mukai1, Hirokazu Wakabayashi1, Atsushi Watanabe1, Hirohiko Ando1, Hiroaki Takashima1, Tetsuya Amano1.   

Abstract

BACKGROUND: There is no echocardiographic predictor of the effectiveness of tolvaptan in patients with heart failure (HF). The aim of this study was to investigate the echocardiographic predictor of responders to tolvaptan in patients with HF.
METHODS: This observational study consisted of 62 consecutive in-hospital patients with HF who received tolvaptan with volume overload despite standard therapies. The echocardiography data were obtained within 1 week before the administration of tolvaptan. Tolvaptan responders were defined as those having a body weight decrease from baseline >1 kg on the morning of day 8.
RESULTS: The mean age of the 62 patients was 75.1 ± 13.9 years, and 45 patients (72.6%) were considered to be responders. Tricuspid annular plane systolic excursion (TAPSE) was significantly higher (17.1 ± 3.8 vs. 13.0 ± 3.9 mm; p = 0.0004) and the tricuspid valve regurgitation pressure gradient (33.3 ± 14.6 vs. 44.9 ± 12.2 mmHg; p = 0.007) and estimated right atrium pressure (7.8 ± 4.2 vs. 10.3 ± 4.5 mmHg; p = 0.043) were significantly lower in the Responder group than in the Non-responder group. In a multivariate logistic regression analysis, TAPSE was found to be an independent predictor of response (odds ratio 1.28; 95% confidence interval 1.03-1.60). According to the receiver operating characteristics analysis, the area under the curve of TAPSE was the largest among the parameters measured by echocardiography. The cut-off value for TAPSE to predict responders was determined to be 17.0 mm (sensitivity = 56.8%, specificity = 94.1%).
CONCLUSIONS: TAPSE is a simple predictor of the effectiveness of tolvaptan in patients with HF.

Entities:  

Keywords:  Echocardiography; Effectiveness of tolvaptan; Right ventricle dysfunction; TAPSE

Mesh:

Substances:

Year:  2017        PMID: 28194742     DOI: 10.1007/s12574-017-0330-z

Source DB:  PubMed          Journal:  J Echocardiogr        ISSN: 1349-0222


  26 in total

1.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

2.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

Authors:  Y Yamamura; S Nakamura; S Itoh; T Hirano; T Onogawa; T Yamashita; Y Yamada; K Tsujimae; M Aoyama; K Kotosai; H Ogawa; H Yamashita; K Kondo; M Tominaga; G Tsujimoto; T Mori
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

3.  Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.

Authors:  Kiyotaka Watanabe; Kaoru Dohi; Tadafumi Sugimoto; Tomomi Yamada; Yuichi Sato; Kazuhide Ichikawa; Emiyo Sugiura; Naoto Kumagai; Shiro Nakamori; Hiroshi Nakajima; Kozo Hoshino; Hirofumi Machida; Shinya Okamoto; Katsuya Onishi; Mashio Nakamura; Tsutomu Nobori; Masaaki Ito
Journal:  J Cardiol       Date:  2012-10-12       Impact factor: 3.159

4.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Authors:  Lisa C Costello-Boerrigter; William B Smith; Guido Boerrigter; John Ouyang; Christopher A Zimmer; Cesare Orlandi; John C Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

5.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

6.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.

Authors:  Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge
Journal:  Eur Heart J       Date:  2006-05-18       Impact factor: 29.983

7.  Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.

Authors:  Keisuke Shimizu; Kent Doi; Teruhiko Imamura; Eisei Noiri; Naoki Yahagi; Masaomi Nangaku; Koichiro Kinugawa
Journal:  Nephrology (Carlton)       Date:  2015-06       Impact factor: 2.506

8.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

Authors:  Michael Domanski; James Norman; Bertram Pitt; Mark Haigney; Stephen Hanlon; Eliot Peyster
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

Review 9.  Congestive renal failure: the pathophysiology and treatment of renal venous hypertension.

Authors:  Edward A Ross
Journal:  J Card Fail       Date:  2012-10-27       Impact factor: 5.712

10.  Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction.

Authors:  Kevin Damman; Gerjan Navis; Tom D J Smilde; Adriaan A Voors; Wim van der Bij; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Eur J Heart Fail       Date:  2007-06-22       Impact factor: 15.534

View more
  1 in total

1.  Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction.

Authors:  Shinichi Nonin; Shinichi Iwata; Asahiro Ito; Soichiro Tamura; Ryoko Kitada; Yu Kawai; Sera Ishikawa; Atsushi Doi; Akihisa Hanatani; Minoru Yoshiyama
Journal:  Int J Cardiol Heart Vasc       Date:  2018-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.